{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=46&state=Ohio", "query": { "state": "Ohio", "city": "Cleveland", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 11338, "total_pages": 1134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=47&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=45&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T16:55:16.183Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02818218", "title": "Superior Vena Cava and Its Relationship to Central Venous Pressure Measurements in Liver Transplantation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Failure" ], "interventions": [ { "name": "Liver Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 58, "start_date": "2016-07-01", "completion_date": "2020-09", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02818218" }, { "nct_id": "NCT03037580", "title": "Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Hypertension", "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Oral treprostinil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 84, "start_date": "2017-08-15", "completion_date": "2019-12-03", "has_results": true, "last_update_posted_date": "2020-11-10", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037580" }, { "nct_id": "NCT07174414", "title": "Cilostazol for Prevention of Recurrent Stroke Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke Recurrence", "Myocardial Infarction", "Vascular Death", "Ischemic Stroke", "TIA (Transient Ischemic Attack)", "Stroke (CVA) or Transient Ischemic Attack", "Recurrent Stroke" ], "interventions": [ { "name": "Cilostazol 100 mg Tablets", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2000, "start_date": "2026-10", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fontana", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174414" }, { "nct_id": "NCT03768414", "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Gallbladder Cancer AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Distal Bile Duct Cancer AJCC v8", "Stage IIIA Gallbladder Cancer AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Distal Bile Duct Cancer AJCC v8", "Stage IIIB Gallbladder Cancer AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Gallbladder Cancer AJCC v8", "Stage IVB Gallbladder Cancer AJCC v8", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2019-02-07", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 692, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03768414" }, { "nct_id": "NCT01914393", "title": "Pediatric Open-Label Extension Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Autism", "Bipolar Depression" ], "interventions": [ { "name": "Lurasidone 20, 40, 60, 80 mg, flexibly dosed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 702, "start_date": "2013-09-30", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2019-12-19", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 35, "location_summary": "Dothan, Alabama • Downey, California • San Francisco, California + 31 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01914393" }, { "nct_id": "NCT02320721", "title": "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Glargine (HOE901 - U300)", "type": "DRUG" }, { "name": "Insulin Glargine (HOE901 - U100)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1014, "start_date": "2015-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 64, "location_summary": "Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more", "locations": [ { "city": "Saraland", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320721" }, { "nct_id": "NCT00477321", "title": "Safety Study of IL-7 in HIV-infected Patients (Inspire)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Lymphopenia" ], "interventions": [ { "name": "CYT 107", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytheris SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-05", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2012-10-18", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 3, "location_summary": "Miami, Florida • Bethesda, Maryland • Cleveland, Ohio", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477321" }, { "nct_id": "NCT01372787", "title": "Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anxiety", "Fatigue", "Nausea and Vomiting", "Neurotoxicity Syndrome", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Assessment of Therapy Complications", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 103, "start_date": "2011-04-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 144, "location_summary": "Aurora, Colorado • Hartford, Connecticut • New Britain, Connecticut + 105 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01372787" }, { "nct_id": "NCT00636987", "title": "Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Valve Insufficiency", "Aortic Valve Regurgitation", "Aortic Valve Stenosis", "Aortic Valve Incompetence", "Mitral Valve Insufficiency", "Mitral Valve Regurgitation", "Mitral Valve Stenosis", "Mitral Valve Incompetence" ], "interventions": [ { "name": "Biocor and Biocor Supra valves", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2007-04", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Evansville, Indiana + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT00636987" }, { "nct_id": "NCT00083993", "title": "Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Temsirolimus (CCI-779) for 34 months", "type": "DRUG" }, { "name": "Letrozole for 34 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1236, "start_date": "2004-05", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2011-11-08", "last_synced_at": "2026-11-15T16:55:16.183Z", "location_count": 112, "location_summary": "Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083993" } ] }